Macropore Inc. IR-Pages
MacroPore Biosurgery Awarded $750,000 from NIH
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Awarded $750,000 from NIH to Continue Studying the Use of
Adipose-Derived Regenerative Cells for Treating Heart Attack
San Diego, CA, July 27, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(Reuters: MACP.DE) (XMP:GR) announced today that it has been awarded $750,000 to
continue with the second phase of its National Institutes of Health (NIH) Small
Business Innovation Research (SBIR) grant. This grant is for the study of the
potential role of adipose-derived regenerative cells in treating heart attack
and to support future application of these cells in human clinical trials. The
second phase follows the successful completion of the first phase, which
included an award of $100,000.
If you have any questions, please contact: MacroPore Biosurgery, Inc., Stefanie
Bacher (Investor Relations), Phone: +1 858 362 0365, Fax: +1 858 458 0994, e-
mail: sbacher@macropore.com .
end of ad-hoc-announcement (c)DGAP 27.07.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
The research is being conducted in collaboration with W. Robb MacLellan M.D. at
the David Geffen School of Medicine at the University of California, Los
Angeles.
“Heart disease, the leading cause of mortality worldwide, is responsible for 30%
of total global deaths(1) and $40 billion a year in treatment costs(2),” said
Marc H. Hedrick, M.D., President of MacroPore Biosurgery. “Unfortunately, state-
of-the-art treatments are essentially supportive in that they only stabilize or
slow disease progression. Regenerative treatments represent a new class of
therapies for heart disease that have the potential to restore lost heart
function. Even a partial improvement in heart function may substantially reduce
the chronic and costly effects of heart disease. We believe that adipose tissue,
because of its high concentration of regenerative cells, represents an ideal,
real-time source of cells for treating heart disease.”
The SBIR award program encourages small businesses to explore their
technological potential by providing seed money for research and development
projects with the intellectual property rights retained by the small business.
MacroPore Biosurgery has been awarded the maximum allowable amount of $850,000
for this NIH SBIR grant. The primary goal for the first phase grant was to
demonstrate in an animal model that adipose-derived regenerative cells may be
useful for treating heart attack. In the second phase MacroPore Biosurgery will
study the safety and efficacy of these cells in a large animal model of acute
myocardial infarction.
(1) Courtesy of Jain PharmaBiotech Report (January 2004); (2) Courtesy of
American Heart Association
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development
and commercialization of regenerative medicine technologies. We have two
technology platforms, bioresorbable technology and regenerative cell technology.
Our spine and orthopedic implants, derived from our bioresorbable technology,
represent one of the latest advancements in spine and orthopedic medicine. They
are manufactured by us and distributed exclusively through Medtronic Sofamor
Danek. Within our regenerative cell technology program, we are developing a
system to isolate autologous, homologous-use, regenerative cells.
Simultaneously, we are generating scientific knowledge through internal research
to support the clinical use of these cells. Our most advanced research and
development program is in the repair of cardiovascular tissues that are damaged
after a heart attack. We are also researching applications in bone repair,
spinal disc regeneration, and cosmetic and reconstructive surgery. For further
information please visit our web site http://www.macropore.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to update any revision of forward-looking statements
to reflect events, trends or circumstances after the date they are made.
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
270800 Jul 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found